Recent advances using FcRn overexpression in transgenic animals to overcome impediments of standard antibody technologies to improve the generation of specific antibodies

Imre Kacskovics,1,2,* Judit Cervenak,1 Anna Erdei,2 Richard A. Goldsby3 and John E. Butler4

1ImmunoGenes Ltd.; Budakeszi, Hungary; 2Department of Immunology; Eötvös Loránd University; Budapest, Hungary; 3Department of Biology; Amherst College; Amherst, MA USA; 4Department of Microbiology; University of Iowa; Iowa City, IA USA

This review illustrates the salutary effects of neonatal Fc receptor (FcRn) overexpression in significantly improving humoral immune responses in the generation of antibodies for immunotherapy and diagnostics. These include: (1) improved IgG protection; (2) augmented antigen-specific humoral immune response with larger numbers of antigen specific B cells, thus offering a wider spectrum of clones; (3) generation of antibodies against weakly immunogenic antigens; (4) significant improvements in the number and substantial developments in the diversity of hybridomas. FcRn transgenesis thus confers a number of practical benefits, including faster antibody production, higher antibody yields and improved generation of hybridomas for monoclonal antibody production. Notably, these efficiencies in polyclonal antibody production were also demonstrated in FcRn transgenic rabbits. Overall, FcRn transgenic animals yield more antibodies and provide a route to the generation of antibodies against antigens of low immunogenicity that are difficult to obtain using currently available methods.

Introduction

Maintenance of antibody (Ab) levels requires continuous secretion of immunoglobulin (Ig) by plasma cells and protection from degradation. IgG is a class of Abs that is unique to mammals. It is the most abundant Ab in serum and is also passively transferred to mammalian offspring. From the standpoint of therapeutic or diagnostic Ab reagent production, it is the most important Ab class when preparing an Ab reagent.

In 1958, Brambell described a saturable receptor that mediates the transport of maternal γ-globulin to the fetus;1 he then inferred the presence of a similar or identical receptor that protected gamma-globulin from catabolism to make it the longest surviving of all plasma proteins.2 At about the same time, it was shown that 7 S γ-globulin (IgG) is the fraction of Ig that was protected by such a mechanism;3 a few years later, it was also shown IgG that mediates maternal immune transport in mammals.4,5

The neonatal Fc receptor (FcRn) was first identified in the 1970s as the protein that mediates transfer of maternal, milk-borne IgGs across the rodent neonatal intestine.6 Subsequently, FcRn was shown to be a heterodimer of two polypeptides that binds IgG in a strictly pH dependent way, with binding occurring at slightly acidic pH and no detectable binding at pH 7.4,7,8 Later it was shown that the functional FcRn is composed of an MHC class-I like α-chain and β2-microglobulin (β2m).9 FcRn orthologs have been isolated from mouse, rat, human, sheep, cow, possum, pig and camel, suggesting that this receptor is present in essentially all mammalian species.10,11 The unique ability of this receptor to modulate the half-life of IgG and albumin has guided engineering of novel therapeutics.12,13 More recently, several publications have shown that FcRn plays major roles in antigen-IgG immune-complex phagocytosis by neutrophils,14 and also in antigen presentation of IgG immune complexes by professional antigen presenting cells.15-18

We and others have shown that higher than normal expression levels of FcRn reduced exogenous IgG catabolism in transgenic animals, resulting in higher circulating levels of IgG.19-21 Our more recent studies have demonstrated that FcRn overexpression in transgenic mice not only augments rescue of antigen-specific IgG, but also enhances the expansion and diversity of antigen-specific B cells and plasma cells in secondary lymphoid organs. Furthermore, we found that these transgenic mice were able to mount substantial humoral responses against weakly immunogenic antigens and to improve hybridoma production efficiency without any sign of autoimmunity.22-24

We summarize here the effects that contribute to the enhancement of IgG formation and protection in transgenic animals that overexpress FcRn. We also discuss the emerging opportunities enabled by these advances for medical and biological applications of monoclonal and polyclonal antibodies.

Ab Reagents are Critical in Immunotherapy and Diagnostics

Abs raised in a number of different species serve as powerful tools in biology and medicine. These molecules were initially produced
animals carrying and expressing multiple copies of FcRn can be safely bred, resulting in offsprings with elevated expression of FcRn and displaying enhanced immune responses, clearly demonstrating that FcRn transgenic lines can be generated for experimental and developmental purposes.

**Transgenic Mice that Overexpress FcRn Show Improved IgG Protection**

FcRn has been shown to play a central role in regulating the transport of maternal IgG to fetuses or newborns within and across cells of diverse origin, and it also serves to rescue IgG and albumin from degradation, thereby regulating their homeostasis throughout adult life. The multiple functions of FcRn are dependent on its ability to sort monomeric IgG away from lysosomal degradation within cells and release bound cargo during exocytic events at the plasma membrane (Fig. 1A). The fact that the FcRn salvage pathway is saturable is a well-known phenomenon referred to as fractional catabolic rate and caused by the fact that the pool of FcRn available in cells to recycle or transport its ligand can be limited. Thus, when FcRn is fully saturated, the unbound ligand is cleared, primarily through lysosomal degradation. The prolonged IgG half-life results of the transgenic mice that overexpress FcRn clearly suggest a correlation between the levels of expression of FcRn and the protection of IgG.

Figure 1. (A) The multiple functions of FcRn are dependent on its ability to sort monomeric IgG away from lysosomal degradation within cells and release bound cargo during exocytic events at plasma membrane. (B) The fact that FcRn salvage pathway is saturable is a well-known phenomenon referred to as fractional catabolic rate and caused by the fact that the pool of FcRn available in cells to recycle or transport its ligand can be limited. Thus, when FcRn is fully saturated, the unbound ligand is cleared, primarily through lysosomal degradation. (C) The prolonged IgG half-life results of the transgenic mice that overexpress FcRn clearly suggest a correlation between the levels of expression of FcRn and the protection of IgG.
In addition, exploitation of the Fc/FcRn interaction is proving to be a generalized way to extend pharmacokinetics of the therapeutic mAb and Fc-fusion proteins. Pharmacokinetic studies in mice lacking the endogenous FcRn and transgenic for human FcRn (hFcRn), showed that the efficiency of human IgG (hIgG) protection was higher when mice expressed high level of hFcRn. This model also proved useful for studies of the catabolism of different hIgGs.

In our earlier studies, we cloned the bovine FcRn (bFcRn), and confirmed the presence of its transcripts in multiple mucosal epithelial and capillary endothelial cells, which are considered to transport or protect IgG as in other mammalian species. Furthermore, our in vivo studies in “normal” and transchromosome cattle expressing hIgG indicated that the bFcRn is involved in IgG catabolism in this species, and that the bFcRn binds and efficiently protects both bovine and human IgGs. We recently created two types of transgenic mice that overexpressed the bFcRn to analyze its regulation, its role in mammary gland IgG secretion and its function in the humoral immune response.

In our first model, transgenic mice (on Chinese Kunming White genetic background) that carry the endogenous mouse FcRn (mFcRn), and transgenes encoding the bFcRn α-chain and bovine β2m and driven by the mammary gland-specific β-casein promoter, express high levels of the bFcRn in their lactating mammary glands. We used this model to test whether this receptor mediates the transfer of IgG from plasma to milk. Significantly increased IgG levels were observed in the sera and milk from transgenic animals, suggesting that the overexpressed bFcRn could bind and protect endogenous mouse IgG (mIgG) and thus extend its lifespan. We also found that injected hIgG showed a significantly longer half-life (7–8 days) in the transgenic mice than in controls (2.9 days). Altogether, the data suggested that bFcRn could bind both mouse and human IgGs, showing a cross-species FcRn-IgG binding activity. However, we found no selective accumulation of endogenous mIgG or injected bovine IgG (bIgG) in the milk of the transgenic females, supporting a previous hypothesis that the role of FcRn in the mammary gland is to recycle IgG from this tissue to the blood instead of secreting it to the milk.

In our second model, transgenic mice (originally in FVB/N genetic background) carry a 102 kb bovine genomic fragment in a bacterial artificial chromosome (BAC) containing the bFcRn α-chain gene (bFCGRT) with its 44 kb 5’ and 50 kb long 3’ flanking sequences. Mice in one line (#14), carry 2 copies if they are heterozygous (hemizygous) (FVB/N_Tg4) or 4 copies if homozygous (FVB/N_Tg4), while mice in the other line (#19) carry 5 copies if they are hemizygous (FVB/N_Tg5) or 10 copies if homozygous (FVB/N_Tg10) of the bFCGRT, respectively, together with the endogenous mFcRn. bFcRn was detected in multiple tissues that express FcRn endogenously, and its expression was copy-number related (at both the mRNA and protein levels). FVB/N_Tg4 demonstrated significantly extended half-life of mIgG, indicating that bFcRn forms a functional complex with the mouse β2m and thus binds and protects mouse IgG. These experiments also suggest that the cytoplasmic domain of the bFcRn is properly involved in signal transduction in mouse cells. Although the cytoplasmic domain of the bFcRn is shorter by 10 amino acid residues than the mFcRn, they do not differ in the key cytosolic tail motifs that are important for intracellular trafficking. We also found that injected hIgG showed a significantly longer half-life in FVB/N_Tg4 mice (7.6 days) than in controls (4.5 days) (unpublished observation). The IgG clearance results of these transgenic mice that overexpress FcRn clearly suggest a correlation between the levels of expression of FcRn and the protection of IgG (Fig. 1C).

**Augmented Antigen-Specific Humoral Immune Response and Increased Numbers of Antigen-Specific B Cells in bFcRn Transgenic Mice**

It was of greatest interest to know whether better protection of IgG in bFcRn transgenic mice results in increased levels of antigen-specific antibody and B cells following immunization. Using mice carrying extra copies of the bFcRn α-chain, we demonstrated that immunization with ovalbumin (OVA), TNP haptenated protein and, interestingly, an influenza vaccine, generated significant increases in the immune response compared with wild-type controls. We also created a congenic strain that carries five copies of the bFcRn on BALB/c genetic background (BALB/c_Tg5) that showed similar immune responses, which indicated that these FcRn-mediated effects are not strain dependent. We demonstrated that the transgene (bFCGRT) was integrated as tandem repeats in the two bFcRn transgenic lines (#14 and #19) in two different chromosomes, indicating that the immune phenotype we observed was not due to insertional mutagenesis of unidentified gene(s) at transgene integration sites, but was dependent on bFcRn overexpression. In our experiments, transgenic mice generated multiple fold higher levels of antigen-specific IgG titers compared with their controls and the average affinity of the antigen-specific Abs generated in transgenic mice were at least as good as in the wild-type controls, implying appropriate affinity maturation in both groups. Importantly, the virus neutralization capability of the influenza specific Abs was doubled in transgenic sera as compared to the wild-type controls. The peak value of the IgG levels in transgenic mice was very high in many cases (around 40 mg/ml in OVA immunization) and persisted relatively long times, supporting previous findings that high IgG levels were maintained in transgenic animals overexpressing the bFcRn.

Measurements made during several studies revealed that not only the antigen-specific IgG, but also the IgM titers, were increased during the secondary immune response in transgenic but not in wild-type mice. Since IgM does not interact with FcRn, we concluded that the robust antigen-specific Ab production in these transgenic animals was the result of the additive effect of a better IgG protection and an augmented immune response in lymphoid organs. This assumption was confirmed by the findings that after immunization, the spleens from transgenic mice were significantly larger and contained many more cells compared with the wild-type controls. Moreover, an enhanced expansion of antigen-specific B-cell clones in the spleen of the
transgenic mice was observed (Fig. 2).\textsuperscript{22-24} Pursuit of this finding by analysis of the splenic cell population before and after OVA immunization showed that the spleen of the transgenic mice contained slightly more B and T cells, but twice to three times as many granulocytes, dendritic cells and plasma cells as their wild-type controls.\textsuperscript{22-24}

High Level of Specific Antibodies against Weakly Immunogenic Antigens: Influenza Epitope in bFcRn Transgenic Mice

The higher level of antigen-specific IgG in transgenic animals leads to the formation of more immune complexes (ICs). The ability of these ICs to induce potent humoral immune responses has long been known. Keler et al. have shown that targeting foreign antigen to human FcγRI (CD64) in transgenic mice expressing human CD64 can overcome immunological non-responsiveness to a weak immunogenic antigen.\textsuperscript{42} In this case the antigen is linked to an IgG/Fc region as a specific targeting molecule and thus, due to feasibility reasons, this approach is intended to facilitate human vaccination\textsuperscript{43} instead of routine use in Ab production. Among the possible explanations for the increased B-cell activity in bFcRn transgenic mice is the much increased antigen-specific IgG level that results in more ICs, and thus mimics the natural mechanism to target the antigen to Fc receptors. Furthermore, FcRn overexpression leads to augmented antigen processing in professional antigen presenting cells (unpublished data), which also increases B-cell activation. The elevated antigen-specific IgM level, as well as the many more antigen-specific IgM producer cells (analyzed by ELISPOT assays) observed during the secondary immune response in the transgenic mice, are the result of the more potent activation of naïve B cells in transgenic mice, which suggests increased diversification of the antigen-specific Ab repertoire through the recruitment of novel B-cell clonotypes as was demonstrated in a recent study in reference 44.

One of the interesting questions surrounding this augmented immune response is whether these transgenic mice would effectively induce immune responses to weakly immunogenic antigens. To address this question, we immunized the bFcRn transgenic mice with a series of weak antigens from influenza virus and a G protein-coupled receptor.

In one of these experiments, we used a highly conserved hemagglutinin subunit 2 (HA2)-based synthetic peptide that was recently found to be effectively targeted by neutralizing antibodies.\textsuperscript{45-47} Using an ELISA system, we found that, whereas wild-type mice showed a weak immune response and developed only a de minimis amount of antibody against the epitope, FcRn overexpressing transgenic animals mounted a robust reaction expressed in specific antibody titers on day 28 that continued to rise through day 50. Consistent with our previous data, the enhanced immune response resulting from the FcRn overexpression was also associated with a substantial increase in the number of spleen derived B cells, dendritic cells, granulocytes and plasma cells (Fig. 3).\textsuperscript{22}

Based on this observation, we propose that transgenic mice that overexpress bFcRn offer major advantages in antibody formation by allowing the generation of Abs (and hybridomas) to weakly immunogenic antigens that otherwise would be difficult or even impossible to effectively target. Experiments conducted in collaboration with other teams using a selection of their targeted antigens corroborated these findings.\textsuperscript{48}

Transgenic bFcRn-Mediated Immune Response Augments the Diversity of Antibodies Induced

Encouraged by experimental results that consistently demonstrated a superior immune response capability in FcRn overexpressing animals, we investigated the diversity of the induced antibodies in these animals. We have recently shown by using
epitope mapping that the addressed number of epitopes is substantially increased in our transgenic animals (unpublished data).

**FcRn Overexpression Improves Hybridoma Production Efficiency**

mAbs have become essential tools in scientific, diagnostic and therapeutic applications. Increasing demand for new or more specific mAbs, as well as efforts to reduce the number of laboratory animals, has led to development of genetically modified mouse strains that potentially increase hybridoma production. As antigen-specific B cells in the spleen were multiplied in the bFcRn transgenic mice,\textsuperscript{12,24} we speculated that this phenomenon might result in higher hybridoma production in these animals. To address this question, we immunized these transgenic mice and their wild-type controls with trinitrophenylated proteins, generated hybridomas and analyzed their numbers and specificities. We observed that transgenic mice generated a 3–5-fold increase in antigen-specific IgG titers and had significantly larger spleens containing higher number of antigen-specific B cells and plasma cells, analyzed by ELISA and ELISPOT assays. Fusion of the isolated splenocytes with standard mouse myeloma cells (SP2/0-Ag14) resulted in a 2- to 6-fold increase in number of hapten- or carrier-specific IgM and IgG positive microcultures, indicating that overexpression of the bFcRn does not inhibit the fusion or reduce viability of the hybridomas. We also analyzed the hybridization frequencies (number of hybridoma clones per 10\textsuperscript{8} spleen cells used in the fusion) and found a several-fold increase in antigen-specific microcultures per splenocytes in transgenic mice compared with controls.\textsuperscript{23} More recent experiments conducted in collaboration with other teams using a selection of their targeted antigens corroborated these findings.\textsuperscript{58}

**FcRn Overexpression Does Not Elicit Autoimmunity**

Whereas further advances in animal immunization technologies are expected to be slim, transgenic animals have the potential to substantially improve antibody production.\textsuperscript{49} Previous publications have described the use of genetically altered mouse strains deficient in genes that inhibit B-cell apoptosis or the elimination of the FcγRIIB that inhibits B-cell activation (Fas deficiency, Bcl-2 transgenesis and FcγRIIB deficiency) to improve the efficiency of hybridoma production.\textsuperscript{50–53} Although, the humoral immune response is augmented in these mice, they generate a large number of autoreactive B cells. In addition, they spontaneously develop immune complex-mediated diseases.\textsuperscript{54–58} These examples demonstrate that immune hyper-responsiveness can result in vulnerability to autoimmune disease.

To rule out the possibility that enhanced humoral responses in bFcRn transgenic animals are accompanied by dysregulation of B cell selection, we carried out an antibody profiling assay suitable for the monitoring of autoimmune diseases.\textsuperscript{59} Non-immunized, 7–8 months old bFcRn transgenic animals showed the same general antibody profile as wild-type littermates, with no detectable antinuclear antibodies. Thus, enhanced immune responsiveness in these transgenic mice did not result in the development of spontaneous autoimmunity and autoimmune characteristics do not limit the use of these animals in Ab production.\textsuperscript{23}

The ability of ICS to induce potent humoral immune responses has long been known. A series of early experiments\textsuperscript{60–63} demonstrated the activating capacity of these complexes, finding them able to enhance Ab production. More recently, it was demonstrated that in the presence of ICS formed in vivo between the antigen and pre-existing Abs from the primary response activate naïve B cells, inducing them to respond with accelerated kinetics and increased magnitude during the secondary immune response.\textsuperscript{54,64} Based on these reports, we propose that the elevated antigen-specific IgM and IgG levels during secondary immune response were the result of the more potent activation of naïve and memory B cells in transgenic mice. An important implication of the augmented naïve B-cell activation during antigen re-exposure in transgenic mice is that it increases diversification of the antigen-specific Ab repertoire.

Our data show a robust neutrophil granulocyte influx in immunized wild-type and transgenic mice. This is consistent with other recent observations, showing that in the presence of ICS the main antigen-specific cells recruited in draining lymph nodes were neutrophils.\textsuperscript{55–57} Since transgenic mice produced much more antigen-specific IgG than the controls, we concluded that the difference in the number of neutrophils we observed
in the transgenic compared with the wild-type mice can be explained at least partly by the greater amount of antigen-specific IgG ICs formed or transported by neutrophils in transgenic animals. The emerging evidence of the important and multifaceted roles of neutrophil granulocytes in potentiating the adaptive immune response in the secondary lymphoid organs have been recently reviewed in reference 68. Furthermore, since FcRn is expressed in neutrophils and plays an active role in phagocytosis, we also analyzed this function in transgenic mice. We found that bFcRn is expressed in transgenic neutrophils and they phagocytose IgG immune complexes more efficiently than their wild-type controls. We believe that this effect further boosts neutrophil activation, and that their influx into draining secondary lymphoid tissue contributes to the enhanced B-cell activation we observed in transgenic mice.

We also found that bFcRn is expressed in bone marrow derived dendritic cells and they phagocytose IgG immune complexes and activate T cells more efficiently than their wild-type controls (unpublished data). The higher number of dendritic cells in transgenic FcRn animals compared with the wild-type controls after immunization suggests that these cells are more abundant and active in the spleen of transgenic mice and certainly contribute to the augmented immune response we observed.22,24

**Transgenic Animals that Overexpress FcRn Act through a Combination of IgG Protection, Expansion of the B-Cell Repertoire and Improved Antigen-Presentation**

At the beginning of our research, the role of the FcRn in modulating the immune response via clonal expansion of B cells was a striking and unexpected finding. Studies have variably reported that IgG responses to antigenic stimuli are reduced69-71 or increased72,73 in β2m-deficient mice that lack functional FcRn. On the other hand, impairment of IgG synthesis was not detected in FcRn α-chain knock-out animals, and the low serum IgG levels were explained by the impaired IgG protection.35 However, FcRn expression and its role in professional APCs, which have essential roles in humoral immune response, have been recently described in references 15–18, 74 and 75. These studies indicate that the FcRn efficiently increases phagocytosis and recycles monomeric IgG out of these cells, and also that it directs IgG-antigen immune complexes into lysosomes.15,16 This latter function is further supported by showing that the MHC class II associated invariant chain, which is generally restricted to APCs, can associate with FcRn and direct it into lysosomes.76 Taken together, the data therefore indicate that FcRn redirects antigens complexed with IgG into degradative compartments that are associated with the loading of antigenic peptides onto MHC class II molecules within cells.11 The higher number of dendritic cells in transgenic FcRn animals compared with the wild-type controls after immunization suggests that these cells are more abundant and active in the spleen of transgenic mice and certainly contribute to the augmented immune response we observed.22,24 This could be due to the higher level of ICs in transgenic mice and their increased phagocytosis and antigen presentation (unpublished data).
Based on these results, we suggest that the overexpression of the FcRn not only rescues the antigen-specific IgG at a greater level, but also enhances the priming of naïve B cells, the expansion of antigen-specific memory B cells and plasma cells in the secondary lymphoid organs. A more recent study that demonstrates the FcRn mediated antigen presentation in T-cell proliferation and antigen-specific Ab responses supports our observations (Fig. 4).

Conclusion

For the past 35 years, hybridoma technology has enhanced our capacity for research and development of diagnostics by providing mAb reagents to track, detect and quantify target molecules in cells and serum. Recently, several more advanced methods to harness the immune response have substantially increased the number of antibody-producing cells that can be screened. Moreover, mAbs isolated from human display libraries have proved extremely useful in the characterization of structural epitopes that mediate neutralization. Caveats to this methodology exist, however, since phage display libraries are generated by random combination of immunoglobulin VH and VL genes and are therefore not restricted, as the in vivo repertoire is, by mechanisms regulating the production of auto-reactive specificities.

We propose that the effects we observed in transgenic mice that overexpress bFcRn offer major advantages in mAb production, where the goal is to generate a large pool of antigen-specific B cells, especially against weakly immunogenic proteins and peptides.

Our most recent results in transgenic rabbits that overexpress FcRn demonstrate an augmented immune response, similar to that described in this review for mice. This indicates that the adaptation of this technology to larger mammals will bring substantial advantages for the production of polyclonal Ab, as well as for the formation of mAb in species other than mice.

Furthermore, the introduction of overexpressing bFcRn in humanized animal models may endow these animals with an enhanced capacity to mount substantial Ab responses and overcome their intrinsically weakened immune system. It is well known that the immune response in transgenic mice or other transgenic species expressing human IgGs is less robust than in strains that are used to generate homologous mAbs. As a consequence an increased number of immunizations or antibody screens might be required or there may be a complete failure to generate mAbs in these animals. Based on our current observations and previous findings (e.g., strong binding of the bovine FcRn to human IgG19,39), we believe that there is good reason to expect that the overexpression of the bFcRn has the potential to improve the immune response of the humanized animals.

For the reasons outlined here, bFcRn transgenesis can be expected to enrich the choices for antibodies against many targets that were previously un-addressable. Our studies suggest that the enlarged armamentarium of Abs against critically important antigens and specific epitopes will have a transformational effect in facilitating the derivation and development of antibody-based therapies, diagnostics and other tools. Moreover, the improvements in harvestable quantities of high-quality antibodies will likely afford substantial and enabling efficiencies in making them available as important compounds for medical and biological purposes.

Acknowledgments

Supported by the grant OM-00117-119/2008 from the Hungarian National Office for Research and Technology and ImmunoGenes Ltd., Hungary.

References

1. Brambell FW, Halliday R, Morris IG. Interference by human and bovine serum and serum protein fractions with the absorption of antibodies by suckling rats and mice. Proc R Soc B 1958; 149:1.
2. Brambell FW, Hemmings WA, Morris IG. A theoretical model of gammaglobulin catabolism. Nature 1964; 203:1352-5.
3. Spiegelberg HL, Weigle WO. The catabolism of homologous and heterologous 7s gamma globulin fragments. J Exp Med 1965; 121:323-38.
4. Kranenbuhl JP, Campiche MA. Early stages of intestinal absorption of specific antibodies in the newborn. An ultrastructural, cytochemical and immunological study in the pig, rat and rabbit. J Cell Biol 1969; 42:345-65.
5. Butler JE. Transmission of immunity from mother to young. In: Hasagawa T, Hayashi M, Ebhing FJG, Henderson FW, Eds. Fertility and Sterility. Amsterdam: Excerpta Medica 1971; 92-8.
6. Jones EA, Waldmann TA. The mechanism of intestinal uptake and transcellular transport of IgG in the neonatal rat. J Clin Invest 1972; 51:2916-7.
7. Rodewald R, Kranenbuhl JP. Receptor-mediated transport of IgG. J Cell Biol 1984; 99:159-64.
8. Siminer NE, Mostov KE. An Fc receptor structurally related to MHC class I antigens. Nature 1989; 337:184-7.
9. Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 2007; 7:715-25.
10. Ward ES, Ober RJ. Chapter 4: Multistaging by exploitation of intracellular transport functions the many faces of FcRns. Adv Immunol 2009; 103:77-115.
11. Roopenian DC, Sun VZ. Clinical ramifications of the MHC family Fc receptor FcRn. J Clin Immunol 2010; 30:790-7.
12. Kuo TT, Baker K, Yoshida M, Qiao SW, Aveson VG, Lencer WI, et al. Neonatal Fc receptor: from immunity to therapeutics. J Clin Immunol 2010; 30:777-89.
13. Vidarsson G, Sternberg AM, Stapleton NM, Splietoff SE, Janssen H, Rebers FE, et al. FcRn: an IgG receptor on phagocytes with a novel role in phagocytosis. Blood 2006; 108:3573-9.
14. Qiao SW, Kobayashi K, Johansen FE, Sollid LM, Splietoff SE, Janssen H, Rebers FE, et al. FcRn: an IgG receptor on phagocytes with a novel role in phagocytosis. Blood 2006; 108:3573-9.
15. Broadley JR, Milford E, et al. Dependence of antibody-mediated presentation of antigen on FcRn. Proc Natl Acad Sci USA 2008; 105:9337-42.
16. Anderson JT, Milford E, et al. Overexpression of the bovine FcRn in the mammary gland results in increased IgG levels in both milk and serum of transgenic mice. Immunology 2007; 122:401-8.
17. Perkova SB, Akilesh S, Spoule TJ, Christianson CJ, Al Khabbaz H, Brown AC, et al. Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humerally mediated autoimmune disease. Int Immunol 2006; 18:1759-69.
18. Baker K, Qiao SW, Kuo TT, Aveson VG, Platerz, Andersen JT, et al. Neonatal Fc receptor for IgG (FcRn) regulates cross-presentation of IgG immune complexes by CD1d11b+ dendritic cells. Proc Natl Acad Sci USA 2011; 108:9927-32.
19. Lu W, Zhao Z, Zhao Y, Su S, Zhao Y, Fan B, et al. Overexpression of the bovine FcRn in the mammary gland results in increased IgG levels in both milk and serum of transgenic mice. Immunology 2007; 122:401-8.
20. Egah V, Cervenak J, Jankovic I, Kakavakis I. FcRn overexpression in mice results in potent humoral response against weakly immunogenic antigen. mAbs 2011; 3:173-80.
21. Schneider Z, Cervenak J, Barayza M, Papp K, Prechl J, Lusko G, et al. Transgenic expression of bovine neonatal Fc receptor in mice boosts immune response and improves hybridoma production efficiency without any sign of autoimmunity. ImmunoLett 2011; 137:62-9.
24. Cervenak J, Bender B, Schneider Z, Magna M, Cuesta BV, Liliom K, et al. Neonatal FeR overexpression boosts humoral immune response in transgenic mice. J Immunol 2011; 186:959-68.

25. Collarini EJ, Lee FE, Foord O, Park M, Sperinde G, Wu E, et al. Potent high-affinity antibodies for treat-
ment and prophylaxis of respiratory syncytial virus derived from B cells of infected patients. J Immunol 2009; 183:6338-45.

26. Bozue Z, Huirpi L, Hoffmann O, Kerekes A, Bender B, Kacskovics I. IgG binding FcRn transgenic rab-
bits created through BAC transgenesis. In: Bozue Z, Fan J, Duranthon V, Eds. 4th International Rabbit Biotechnology Meeting. Budapest, Hungary 2011.

27. Humphrey JH, Fahey JL. The metabolism of normal

28. Fahey JL, Robinson AG. Factors controlling serum gamma-globulin concentration. J Exp Med 1963; 118:845-68.

29. Sell S, Fahey JL. Relationship between gamma-globulin metabolites and low serum gamma-globin in
germ-free mice. J Immunol 1946; 93:81-7.

30. Junghans RP, Anderson CL. The protection receptor for IgG catalyzes the beta2-microglobulin-contain-
ing neonatal intestinal transport receptor. Proc Natl Acad Sci USA 1999; 96:15245-54.

31. Waldmann TA, Stober W. Metabolism of immuno-
globulins. Prog Allergy 1969; 13:1-110.

32. Bleeker WK, Teeling JL, Hack CE. Accelerated auto-
nobody clearance by intravenous immunoglobulin therapy; studies in experimental models to determine the magnitude and time-course of the effect. Blood 2001; 98:3136-42.

33. Andersen SB, Bjostenboe M. Gamma globulin turnover in rabbits before and during hyperimmunization. J Exp Med 1946; 119:537-46.

34. J.P. Taylor, Balbhsar JP. Pharmacokinetic and pharmacodynamic effects of high-dose monoclonal antibody therapy in a rat model of immune thrombocy-
topenia. Aap s 2005; 7:895-902.

35. Roopenian DC, Christianson GJ, Sproule TJ, Brown AC, Akilek S, Jung N, et al. The MHC class I-like IgG

36. Andersen SB, Bjostenboe M. Gamma globulin turnover in rabbits before and during hyperimmunization. J Exp Med 1946; 119:537-46.

37. Kacskovics I, Wu Z, Simister NE, Frenyo LV, Hammarstrom L. Cloning and characterization of the human MHC class I-like Fc receptor. J Immunol 2000; 164:1889-97.

38. Mayer B, Zolnai A, Frenyo LV, Jancsoik V, Szentimray Z, Hammarstrom L, et al. Redistribution of the sheep neonatalFc receptor in the mammary gland around the time of parturition in ewes and its localization in the small intestine of neonatal lambs. Immunology 2002; 107:288-96.

39. Mayer B, Kis Z, Kajan G, Frenyo LV, Hammarstrom L, Kacskovics I. The neonatal Fc receptor (FcRn) is expressed in the bovine lung. Vet Immunol Immunopathol 2004; 98:85-9.

40. Kacskovics I, Kis Z, Mayer B, West AF Jr, Tiango NE, Tilahun M, et al. FcRn mediates elongated serum half-life of human IgG in cattle. Int Immunol 2006; 18:525-36.

41. Kusaba M, Kinanishi P, Choi YJ, Nareen R, Tomizuka K, Sullivan EJ, et al. Cloned transchromosomal calves producing human immunoglobulin. Nat Biotechnol 2002; 20:889-94.

42. Cianga P, Medesac C, Richardson JA, Ghetie V, Ward ES. Identification and function of neonatal Fc receptor in mammalian gut: a metagenomic screen. Eur J Immunol 2001; 31:245-9.

43. Keler T, He L, Graziano RF. Development of antibody-
targeted vaccines. Curr Opin Mol Ther 2007; 7:157-63.

44. Gois CL, Chappell CR, Shaadshaharamy R, Selvaraj P, Jacob J. Immune complex-mediated enhancement of secondary antibody responses. J Immunol 2010; 184:2629-8.

45. Eckert DC, Bubba G, Elsiger MA, Friesen RH, Jongeneelen M, Throsby M, et al. Antibody recogni-
tion of a highly conserved influenza virus epitope. Science 2009; 324:426-71.

46. Sui J, Hwang WC, Perez S, Wei G, Aird D, Chen LM, et al. Structural and functional bases for broad-
spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 2009; 16:265-73.

47. Throsby M, van den Brink E, Jongeneelen M, Poon LL, Al sad R, Cornelissen L, et al. Heterobysyctic

48. van De Winkel JG, Deo YM, et al. Targeting weak antigens to CD64 elicits potent humoral responses in human CD64 transgenic mice. J Immunol 2000; 165:6738-42.
79. Reddy ST, Ge X, Miklos AE, Hughes RA, Kang SH, Hoi KH, et al. Monoclonal antibodies isolated without screening by analyzing the variable-gene repertoire of plasma cells. Nat Biotechnol 2010; 28:965-9.
80. Wang TT, Tan GS, Hai R, Pica N, Petersen E, Moran TM, et al. Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins. PLoS Pathog 2010; 6:1000796.
81. Carter PJ. Potent antibody therapeutics by design. Nat Rev Immunol 2006; 6:343-57.